ANI PHARMACEUTICALS INCANIPEarnings & Financial Report
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Revenue
$197.1M
Gross Profit
N/A
Operating Profit
$26.2M
Net Profit
$15.7M
Gross Margin
N/A
Operating Margin
13.3%
Net Margin
8.0%
YoY Growth
43.4%
EPS
$0.69
ANI PHARMACEUTICALS INC Q1 FY2025 Financial Summary
ANI PHARMACEUTICALS INC reported revenue of $197.1M (up 43.4% YoY) for Q1 FY2025, with a net profit of $15.7M (down 13.9% YoY) (8.0% margin).
Key Financial Metrics
| Total Revenue | $197.1M |
|---|---|
| Net Profit | $15.7M |
| Gross Margin | N/A |
| Operating Margin | 13.3% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
ANI PHARMACEUTICALS INC Q1 FY2025 revenue of $197.1M breaks down across 6 segments, led by Sales Of Generic Pharmaceutical Products at $98.7M (50.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Sales Of Generic Pharmaceutical Products | $98.7M | 50.1% |
| Sales Of Cortrophin Gel | $52.9M | 26.8% |
| Sales Of Established Brands | $25.1M | 12.7% |
| Sales Of ILUVIEN And YUTIQ | $16.1M | 8.2% |
| Unapproved Products | $5.5M | 2.8% |
| Sales Of Royalties And Other Pharmaceutical Services | $4.4M | 2.2% |
ANI PHARMACEUTICALS INC Revenue by Segment — Quarterly Trend
ANI PHARMACEUTICALS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Sales Of Generic Pharmaceutical Products and Sales Of Cortrophin Gel) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Sales Of Generic Pharmaceutical Products | $100.8M | $94.4M | $90.3M | $98.7M |
| Sales Of Cortrophin Gel | $111.4M | $101.8M | $81.6M | $52.9M |
| Sales Of Established Brands | $12.3M | $10.7M | $13.2M | $25.1M |
| Sales Of ILUVIEN And YUTIQ | $19.8M | $16.6M | $22.3M | $16.1M |
| Unapproved Products | $6.5M | $6.0M | $6.1M | $5.5M |
ANI PHARMACEUTICALS INC Annual Revenue by Year
ANI PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $883.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $883.4M |
| 2024 | $614.4M |
| 2023 | $486.8M |
| 2022 | $316.4M |
ANI PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
ANI PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $247.1M | +29.6% | $27.5M | 11.1% |
| Q3 FY2025 | $227.8M | +53.6% | $26.6M | 11.7% |
| Q2 FY2025 | $211.4M | +53.1% | $8.5M | 4.0% |
| Q1 FY2025 | $197.1M | +43.4% | $15.7M | 8.0% |
| Q4 FY2024 | $190.6M | +44.8% | $-10.3M | -5.4% |
| Q3 FY2024 | $148.3M | +12.5% | $-24.2M | -16.3% |
| Q2 FY2024 | $138.0M | +18.4% | $-2.3M | -1.7% |
| Q1 FY2024 | $137.4M | +28.7% | $18.2M | 13.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $137.4M | $138.0M | $148.3M | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M |
| YoY Growth | 28.7% | 18.4% | 12.5% | 44.8% | 43.4% | 53.1% | 53.6% | 29.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $914.5M | $920.8M | $1.29B | $1.28B | $1.29B | $1.34B | $1.41B | $1.44B |
| Liabilities | $437.7M | $440.1M | $856.6M | $855.9M | $849.0M | $881.4M | $902.3M | $899.7M |
| Equity | $452.0M | $455.8M | $405.9M | $403.7M | $418.6M | $436.8M | $505.8M | $540.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $18.3M | $17.4M | $12.5M | $15.9M | $35.0M | $75.8M | $44.1M | $30.4M |